The company has announced the formation of an External Scientific Advisory Board (SAB).
Established on July 21, 2026, this board will provide independent, authoritative scientific guidance for the development of the group's therapeutic pipeline.
The SAB comprises five internationally renowned, multidisciplinary experts.
These members possess deep expertise in RNA delivery technologies, RNAi drug discovery, oncology research and development, clinical translational medicine, chemistry, manufacturing and controls (CMC) activities, and global regulatory compliance for pharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments